Pulmonary hypertension due to left heart disease

Circulation

Volumn 126, Issue 8, 2012, Pages 975-990

  Guazzi, Marco ^a   Borlaug, Barry A ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

heart failure; pulmonary hypertension; pulmonary vasodilators

Indexed keywords

ACETYLCHOLINE; ARGININE; BOSENTAN; CYCLIC GMP; DARUSENTAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; N(G) METHYLARGININE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; SILDENAFIL; TEZOSENTAN;

BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOPULMONARY EXERCISE TEST; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EUROPE; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; HEART VALVE SURGERY; HEMODYNAMIC PARAMETERS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; META ANALYSIS (TOPIC); MITRAL VALVE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; RECEPTORS, ENDOTHELIN; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84865257955     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.085761     Document Type: Review

References (179)

1. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802-1806.
2. Abramson SV, Burke JF, Kelly JJ Jr, Kitchen JG 3rd, Dougherty MJ, Yih DF, McGeehin FC 3rd, Shuck JW, Phiambolis TP. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888-895. (Pubitemid 23034779)
3. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-188. (Pubitemid 32051736)
4. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest. 2007;131:94-100. (Pubitemid 46122979)
5. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119:2663-2670.
6. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53: 1119-1126.
7. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010;7:648-659.
8. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30: 2493-2537.
9. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34:888-894.
10. Kovacs G, Olschewski A, Berghold A, Olschewski H. Pulmonary vascular resistances during exercise in normal subjects: a systematic review. Eur Respir J. 2012;39:319-328.
11. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation. 2008;118:2183-2189.
12. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-595.
13. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-2294.
14. Ristow B, Schiller NB. Obtaining accurate hemodynamics from echocardiography: achieving independence from right heart catheterization. Curr Opin Cardiol. 2010;25:437-444.
15. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and metaanalysis. Heart. 2011;97:612-622.
16. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, Corretti MC, Hassoun PM. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:615-621.
17. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011;139:988-993.
18. Testani JM, St John Sutton MG, Wiegers SE, Khera AV, Shannon RP, Kirkpatrick JN. Accuracy of noninvasively determined pulmonary artery systolic pressure. Am J Cardiol. 2010;105:1192-1197.
19. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-2550. (Pubitemid 47614269)
20. Penicka M, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, Kocka V. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol. 2010;55:1701-1710.
21. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54:S85-S96.
22. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Køber L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146-1150. (Pubitemid 46578202)
23. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-451.
24. West JB, Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation. 1995;92:622-631.
25. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail. 2008;14:695-702.
26. Tsukimoto K, Mathieu-Costello O, Prediletto R, Elliott AR, West JB. Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol. 1991;71:573-582.
27. Saldías FJ, Azzam ZS, Ridge KM, Yeldandi A, Rutschman DH, Schraufnagel D, Sznajder JI. Alveolar fluid reabsorption is impaired by increased left atrial pressure in rats. Am J Physiol. 2001;281: L591-L597.
28. Conforti E, Fenoglio C, Bernocchi G, Bruschi O, Miserocchi GA. Morpho-functional analysis of lung tissue in mild interstitial edema. Am J Physiol. 2002;282:L766-L774. (Pubitemid 34665593)
29. Elliott AR, Fu Z, Tsukimoto K, Prediletto R, Mathieu-Costello O, West JB. Short-term reversibility of ultrastructural changes in pulmonary capillaries caused by stress failure. J Appl Physiol. 1992;73: 1150-1158.
30. Townsley MI, Fu Z, Mathieu-Costello O, West JB. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res. 1995;77: 317-325.
31. Lee JS. Electron microscopic studies on the alveolar-capillary barrier in patients with chronic pulmonary edema. Jpn Circ J. 1979;43: 945-954.
32. Kerem A Yin J, Kaestle SM, Hoffmann J, Schoene AM, Singh B, Kuppe H, Borst MM, Kuebler WM. Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization. Circ Res. 2010;16:1103-1116.
33. Guazzi M, Pontone G, Brambilla R, Agostoni P, Rèina G. Alveolarcapillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J. 2002;23:467-476. (Pubitemid 35204186)
34. Delgado JF, Conde E, Sánchez V, López-Ríos F, Gómez-Sánchez MA, Escribano P, Sotelo T, Gómez de la Cámara A, Cortina J, de la Calzada CS. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005;7:1011-1016. (Pubitemid 41443595)
35. Rabinovitch M. EVE and beyond, retro and prospective insights. Am J Physiol. 1999;277:L5-L12. (Pubitemid 29356745)
36. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethwaite PA. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003;348: 500-509. (Pubitemid 36159885)
37. Stobierska B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol. 2001;38:923-931. (Pubitemid 32912691)
38. Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation. 2002;106: 1618-1621.
39. Cooper CJ, Landzberg MJ, Anderson TJ, Charbonneau F, Creager MA, Ganz P, Selwyn AP. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 1996;93: 266-271. (Pubitemid 26031484)
40. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89:2035-2040. (Pubitemid 24142778)
41. Blitzer ML, Loh E, Roddy MA, Stamler JS, Creager MA. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol. 1996; 28:591-596. (Pubitemid 26288638)
42. Guazzi M, Arena R, Vicenzi M, Guazzi MD. Regulation of alveolar gas conductance by NO in man, as based on studies with NO donors and inhibitors of NO production. Acta Physiol. 2009;196:267-277.
43. Cooper CJ, Jevnikar FW, Walsh T, Dickinson J, Mouhaffel A, Selwyn AP. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998; 82:609-614. (Pubitemid 28397662)
44. Wensel R, Opitz CF, Kleber FX. Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure. J Heart Lung Transplant. 1999;18: 877-883. (Pubitemid 29469448)
45. Porter TR, Taylor DO, Cycan A, Fields J, Bagley CW, Pandian NG, Mohanty PK. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol. 1993;22:1418-1424. (Pubitemid 23316368)
46. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA. 1990;87:5193-5197.
47. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415. (Pubitemid 18090241)
48. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol. 1996;81:1510-1515. (Pubitemid 26349600)
49. Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, Sugishita Y, Goto K, Nishikibe M. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol. 1994;76: 1976-1982. (Pubitemid 24158626)
50. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739. (Pubitemid 23170122)
51. Ray L, Mathieu M, Jespers P, Hadad I, Mahmoudabady M, Pensis A, Motte S, Peters IR, Naeije R, McEntee K. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol. 2008;93:434-442. (Pubitemid 351257694)
52. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
53. Hülsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, Berger R, Woloszczuk W, Putz D, Kos T, Berger R, Woloszczuk W, Maurer G, Pacher R. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol. 1998;32:1695-1700. (Pubitemid 28545210)
54. Saouti N, Westerhof N, Postmus PE, Vonk-Noordegraaf A. The arterial load in pulmonary hypertension. Eur Respir Rev. 2010;19:197-203.
55. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, Mudd JO, Cingolani OH, Borlaug BA, Redfield MM, Lederer DJ, Kass DA. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation. 2012;125:289-297.
56. Lankhaar JW, Westerhof N, Faes TJ, Marques KM, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2006;291:H1731-H1737. (Pubitemid 44497678)
57. Lankhaar JW, Westerhof N, Faes TJ, Gan CT, Marques KM, Boonstra A, van den Berg FG, Postmus PE, Vonk-Noordegraaf A. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J. 2008;29: 1688-1695. (Pubitemid 351957537)
58. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol. 2006;47: 799-803. (Pubitemid 43243104)
59. Borlaug BA. Discerning pulmonary venous from pulmonary arterial hypertension without the help of a catheter. Circ Heart Fail. 2011;4: 235-237.
60. Kondo RP, Dederko DA, Teutsch C, Chrast J, Catalucci D, Chien KR, Giles WR. Comparison of contraction and calcium handling between right and left ventricular myocytes from adult mouse heart: a role for repolarization waveform. J Physiol. 2006;571:131-146.
61. Abel FL, Waldhausen JA. Effects of alterations in pulmonary vascular resistance on right ventricular function. J Thorac Cardiovasc Surg. 1967;54:886-894.
62. Konstam MA, Cohen SR, Salem DN, Conlon TP, Isner JM, Das D, Zile MR, Levine HJ, Kahn PC. Comparison of left and right ventricular end-systolic pressure-volume relations in congestive heart failure. J Am Coll Cardiol. 1985;5:1326-1334. (Pubitemid 15069504)
63. Pagnamenta A, Dewachter C, McEntee K, Fesler P, Brimioulle S, Naeije R. Early right ventriculo-arterial uncoupling in borderline pulmonary hypertension on experimental heart failure. J Appl Physiol. 2010;109: 1080-1085.
64. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120:992-1007.
65. Guazzi M, Pepi M, Maltagliati A, Celeste F, Muratori M, Tamborini G. How the two sides of the heart adapt to graded impedance to venous return with head-up tilting. J Am Coll Cardiol. 1995;26:1732-1740.
66. Tyberg JV, Taichman GC, Smith ER, Douglas NW, Smiseth OA, Keon WJ. The relationship between pericardial pressure and right atrial pressure: an intraoperative study. Circulation. 1986;73:428-432. (Pubitemid 16133020)
67. Atherton JJ, Moore TD, Lele SS, Thomson HL, Galbraith AJ, Belenkie I, Tyberg JV, Frenneaux MP. Diastolic ventricular interaction in chronic heart failure. Lancet. 1997;349:1720-1724. (Pubitemid 27252670)
68. Guazzi MD, Agostoni P, Perego B, Lauri G, Salvioni A, Giraldi F, Matturri M, Guazzi M, Marenzi G. Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J. 1994;72: 534-539. (Pubitemid 24375746)
69. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
70. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121:2592-2600.
71. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838-1842. (Pubitemid 29251016)
72. McDonald MA, Ross HJ. Trying to succeed when the right ventricle fails. Curr Opin Cardiol. 2009;24:239-245.
73. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997;95:1930-1936. (Pubitemid 27164412)
74. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47: 742-748. (Pubitemid 43243094)
75. Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153-159. (Pubitemid 27028733)
76. Pierard LA, Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med. 2004;351: 1627-1634. (Pubitemid 39350423)
77. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17-22. (Pubitemid 32064840)
78. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011:4;257-265.
79. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010; 106:284-286.
80. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN, Zhao DX, Byrne DW. Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009;136:31-36.
81. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139:128-137.
82. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol. 2008;51:679-689. (Pubitemid 351221211)
83. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30:1527-1533. (Pubitemid 27486472)
84. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788-1794.
85. Willens HJ, Chirinos JA, Gomez-Marin O, Fertel DP, Ghany RA, Alfonso CE, Hare JM. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. J Am Soc Echocardiogr. 2008;21:715-719.
86. Mullens W, Borowski AG, Curtin RJ, Thomas JD, Tang WH. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation. 2009;119:62-70.
87. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol. 2010;56:855-863.
88. Bhella PS, Pacini EL, Prasad A, Hastings JL, Adams-Huet B, Thomas JD, Grayburn PA, Levine BD. Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging. 2011;4:482-489.
89. From AM, Lam CS, Pitta SR, Kumar PV, Balbissi KA, Booker JD, Singh IM, Sorajja P, Reeder GS, Borlaug BA. Bedside assessment of cardiac hemodynamics: the impact of noninvasive testing and examiner experience. Am J Med. 2011;124:1051-1057.
90. Pacold I, Hwang MH, Palac RT, Scanlon PJ, Loeb HS. The effects of rapid volume expansion on the right and left cardiac filling pressures after coronary artery bypass surgery. Chest. 1988;93:1144-1147.
91. Boilson BA, Schirger JA, Borlaug, BA. Caveat medicus! Pulmonary hypertension in the elderly: a word of caution. Eur J Heart Fail. 2010;12:89-93.
92. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136:37-43.
93. Soto FJ, Siegel R, Marks D, et al. Performance of pulmonary capillary wedge pressure (PCWP) vs left ventricular end diastolic pressure (LVEDP) in the diagnosis/classification of patients with suspect pulmonary arterial hypertension [abstract]. Chest. 2005;128:137S.
94. Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19: 48-54.
95. Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol. 1996;28: 1775-1780. (Pubitemid 26426234)
96. Guazzi M. Pulmonary hypertension in heart failure with preserved ejection fraction any pathophysiological role of mitral regurgitation. J Am Coll Cardiol. 2009;54:1191-1192.
97. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:191-225.
98. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143-1153.
99. Reindl I, Wernecke KD, Opitz C, Wensel R, König D, Dengler T, Schimke I, Kleber FX. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J. 1998; 136:778-785. (Pubitemid 28506876)
100. Methvin AB, Owens AT, Emmi AG, Allen M, Wiegers SE, Dries DL, Margulies KB, Forfia PR. Ventilatory inefficiency reflects right ventricular dysfunction in systolic heart failure. Chest. 2011;139:617-625.
101. Lewis GD, Shah RV, Pappagianopolas PP, Systrom DM, Semigran MJ. Determinants of ventilatory efficiency in heart failure. The role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail. 2008;1:227-233.
102. Lewis GD, Murphy RM, Shah RV, Pappagianopoulos PP, Malhotra R, Bloch KD, Systrom DM, Semigran MJ. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail. 2011;4:276-285.
103. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, Guazzi M. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007;115:2410-2417. (Pubitemid 46717963)
104. Guazzi M, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol. 2005;46:1883-1890. (Pubitemid 41579812)
105. Murphy RM, Shah RV, Malhotra R, Pappagianopoulos PP, Hough SS, Systrom DM, Semigran MJ, Lewis GD. Exercise oscillatory ventilation in systolic heart failure: an indicator of impaired hemodynamic response to exercise. Circulation. 2011;124:1442-1451.
106. Olson TP, Frantz RP, Snyder EM, O'Malley KA, Beck KC, Johnson BD. Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. Am Heart J. 2007;153: 104.e1-104.e7.
107. Mansfield D, Kaye DM, Brunner La Rocca H, Solin P, Esler MD, Naughton MT. Raised sympathetic nerve activity in heart failure and central sleep apnea is due to heart failure severity. Circulation. 2003; 107:1396-1400. (Pubitemid 36350738)
108. Solin P, Bergin P, Richardson M, Kaye DM, Walters EH, Naughton MT. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation. 1999;99:1574-1579. (Pubitemid 29152924)
109. Francis DP, Willson K, Davies LC, Coats AJ, Piepoli M. Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation. 2000;102:2214-2221.
110. Giannoni A, Baruah R, Willson K, Mebrate Y, Mayet J, Emdin M, Hughes AD, Manisty CH, Francis DP. Real-time dynamic carbon dioxide administration: a novel treatment strategy for stabilization of periodic breathing with potential application to central sleep apnea. J Am Coll Cardiol. 2010;56:1832-1837.
111. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570-578. (Pubitemid 24074931)
112. Kaye DM, Jennings GL, Dart AM, Esler MD. Differential effect of acute baroreceptor unloading on cardiac and systemic sympathetic tone in congestive heart failure. J Am Coll Cardiol. 1998;31:583-587. (Pubitemid 28144125)
113. Saxon LA, Stevenson WG, Middlekauff HR, Fonarow G, Woo M, Moser D, Stevenson LW. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;72:62-65. (Pubitemid 23184364)
114. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105: 1663-1668. (Pubitemid 34298609)
115. Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirk J, Nikitin NP, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010;31:2280-2289.
116. Rickenbacher PR, Trindade PT, Haywood GA, Vagelos RH, Schroeder JS, Willson K, Prikazsky L, Fowler MB. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol. 1996;27:1192-1197. (Pubitemid 26117712)
117. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant. 2000; 19:909-931.
118. Zakir RM, Al-Dehneh A, Maher J, Saric M, Berkowitz RL. Right ventricular failure in patients with preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity. Congest Heart Fail. 2007;13:164-169.
119. Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail. 2011;4:644-650.
120. Braunwald E, Braunwald N, Ross J, Morrow AG. Effects of mitral valve replacement on pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med. 1965;273:509-514.
121. Zener JC, Hancock EW, Shumway NE, Harrison DC. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol. 1972;30:820-826.
122. Levine M, Weinstein J, Diver D, Berman AD, Wyman RM, Cunningham MJ, Safian RD, Grossman W, McKay RG. Progressive improvement in pulmonary vascular resistance following percutaneous mitral valvuloplasty. Circulation. 1989;79:1061-1067. (Pubitemid 19129188)
123. Fawzy ME, Hassan W, Stefadouros M, Moursi M, El Shaer F, Chaudhary MA. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis. 2004;13: 942-947.
124. Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI, Rusinaru D, Szymansky C, Russo A, Suri R, Bacchi Reggiani ML, Branzi A, Modena MG, Enriquez-Sarano M; Mitral Regurgitation International DAtabase (MIDA) Investigators. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J. 2011;32:751-759.
125. Rosario LB, Stevenson LW, Solomon SD, Lee RT, Reimold SC. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol. 1998;32:1819-1824. (Pubitemid 29010440)
126. Haddad F, Ashley E, Michelakis ED. New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Curr Opin Cardiol. 2010;25:131-140.
127. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant. 1993;12:179-184. (Pubitemid 23123857)
128. Braun S, Schrötter H, Schmeisser A, Strasser RH. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int J Cardiol. 2007;115: 67-72. (Pubitemid 44855199)
129. von Scheidt W, Costard-Jaeckle A, Stempfle HU, Deng MC, Schwaab B, Haaff B, Naegele H, Mohacsi P, Trautnitz M; PROPHET Study Group. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant. 2006;25:1070-1076. (Pubitemid 44322050)
130. Sueta CA, Gheorghiade M, Adams KF Jr, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol. 1995;75:34A-43A.
131. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth. 1996;10:864-8. (Pubitemid 26422479)
132. Rex S, Schaelte G, Metzelder S, Flier S, de Waal EE, Autschbach R, Rossaint R, Buhre W. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized- controlled trial. Acta Anaesthesiol Scand. 2008;52:65-72.
133. Martischnig AM, Tichy A, Nikfardian M, Heinz G, Lang IM, Bonderman D. Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure. J Cardiac Fail. 2011;17: 813-818.
134. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982;50: 320-324. (Pubitemid 12059027)
135. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54. (Pubitemid 27329022)
136. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102:1718-1723.
137. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997:96;1976-1982. (Pubitemid 27400761)
138. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y, Kinoshita M. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol. 1997:30;1385-1392. (Pubitemid 27501461)
139. Sütsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, Kim JH, Rickenbacher P, Bertel O. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998:98;2262-2268. (Pubitemid 28533844)
140. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195-197. (Pubitemid 35245980)
141. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11:12-20. (Pubitemid 40215308)
142. Lüscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hürlimann D, Philipp S, Notter T, Noll G, Ruschitzka F. Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106: 2666-2672. (Pubitemid 35364920)
143. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology. 2008;109:273-280. (Pubitemid 351328923)
144. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364: 347-354. (Pubitemid 38970011)
145. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-2019. (Pubitemid 350074798)
146. Argenziano M, Choudhri AF, Moazami N, Rose EA, Smith CR, Levin HR, Smerling AJ, Oz MC. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg. 1998;65:340-345. (Pubitemid 28083325)
147. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant. 1995;14:436-443.
148. Hare JM, Shernan SK, Body SC, Graydon E, Colucci WS, Couper GS. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation. 1997;95:2250-2253. (Pubitemid 27191001)
149. Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelöv B, Wennmalm A, Waagstein F, Lundin S. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant. 1994;13:366-375. (Pubitemid 24168320)
150. Bocchi EA, Bacal F, Auler Júnior JO, Carmone MJ, Bellotti G, Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol. 1994;74:70-72. (Pubitemid 24196320)
151. Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 1995;92:1539-1545.
152. Guazzi M. Clinical use of phophodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail. 2008;1:272-280.
153. Alaeddini J, Uber PA, Park MH, Scott RL, Ventura HO, Mehra MR. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol. 2004;94:1475-1477. (Pubitemid 39556232)
154. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44:2339-2348. (Pubitemid 39647608)
155. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127:1647-1653. (Pubitemid 46218790)
156. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59-66. (Pubitemid 46058612)
157. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, Kettner J, Kautzner J. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009:54;595-600.
158. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-2144. (Pubitemid 350117342)
159. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562. (Pubitemid 47511419)
160. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebocontrolled clinical trial. J Card Fail. 2008;14:189-197. (Pubitemid 351444866)
161. Telford RJ, Hemnes AR, Russel SD, Wittstein IS, Mahmud M, Zaiman AL, Mattai SC, Thiemann DR; Hassoun PM, Girgis RE, Orens JB, Shah AS, Yuh D, Conte JVm Champion HC. PDE5 inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1:213-219.
162. Guazzi M, Vicenzi M, Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail. 2012;14:82-90.
163. Guazzi M. Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124: 164-174.
164. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011;124:2882-2891.
165. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48:622-627. (Pubitemid 44843865)
166. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
167. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116: 238-248. (Pubitemid 47196559)
168. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail. 2012;5:79-86.
169. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122:216-238.
170. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-2273.
171. Healey JS, Davies RA, Tang AS. Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. J Heart Lung Transplant. 2004;23:650-652. (Pubitemid 38595757)
172. Bleeker GB, Schalij MJ, Nihoyannopoulos P, Steendijk P, Molhoek SG, van Erven L, Bootsma M, Holman ER, van der Wall EE, Bax JJ. Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol. 2005;46: 2264-2269. (Pubitemid 41785495)
173. Shalaby A, Voigt A, El-Saed A, Saba S. Usefulness of pulmonary artery pressure by echocardiography to predict outcome in patients receiving cardiac resynchronization therapy heart failure. Am J Cardiol. 2008;101: 238-241.
174. Haddad H, Elabbassi W, Moustafa S, Davies R, Mesana T, Hendry P, Masters R, Mussivand T. Left ventricular assist device as bridge to heart transplantation in congestive heart failure with pulmonary hypertension. ASAIO J. 2005;51:456-460. (Pubitemid 41076783)
175. Mikus E, Stepanenko A, Krabatsch T, Loforte A, Dandel M, Lehmkuhl HB, Hetzer R, Potapov EV. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg. 2011;40:971-977.
176. Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, Huber L, Grimm M, Rajek A, Wolner E, Wieselthaler G. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg. 2007;133:689-695.
177. Etz CD, Welp HA, Tjan TD, Hoffmeier A, Weigang E, Scheld HH, Schmid C. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg. 2007;83: 1697-1705. (Pubitemid 46616800)
178. Torre-Amione G, Southard RE, Loebe MM, Youker KA, Bruckner B, Estep JD, Tierney M, Noon GP. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. J Heart Lung Transplant. 2010;29:195-200.
179. Liden H, Haraldsson A, Ricksten SE, Kjellman U, Wiklund L. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance? Eur J Cardiothorac Surg. 2009;35:1029-1034.